Breaking News
Get 40% Off 0
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list
Close

Vaccinex Inc (VCNX)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Vaccinex's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
4.860 +0.160    +3.40%
16:00:00 - Closed. Currency in USD ( Disclaimer )
After Hours
4.800
-0.060
-1.235%
18:33:03 - Real-time Data
Type:  Equity
Market:  United States
  • Volume: 7,768
  • Bid/Ask: 4.630 / 5.100
  • Day's Range: 4.630 - 5.010
Vaccinex 4.860 +0.160 +3.40%

Vaccinex Inc Company Profile

 
Get an in-depth profile of Vaccinex Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

41

Equity Type

ORD

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company’s lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. Its Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer’s Disease, with ongoing exploration of potential Phase 3 development in Huntington’s disease. It has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. The company was incorporated in 2001 and is headquartered in Rochester, New York.

Contact Information

Address 1895 Mount Hope Avenue
Rochester, 14620
United States
Phone 585 271 2700
Fax 585 271 2765

Top Executives

Name Age Since Title
Maurice Zauderer 75 2001 Co-Founder, CEO, President & Director
Albert D. Friedberg 74 2001 Chairman of the Board
Bala S. Manian 77 2004 Independent Director
Leisha A Emens - - Scientific & Clinical Advisor
Ramesh Ramanathan - - Scientific & Clinical Advisor
Max Vasquez - - Member of Scientific & Clinical Advisory Board
Amita Patnaik - - Scientific & Clinical Advisor
Laura J. Balcer - - Scientific & Clinical Advisor
Steven L. Galetta - - Scientific & Clinical Advisor
Charles Warren Olanow - - Scientific & Clinical Advisor
David M. Essayan - - Scientific & Clinical Advisor
Gerald E. Van Strydonck 77 2003 Independent Director
Andrew Feigin - - Scientific & Clinical Advisor
Ray Dorsey - - Scientific & Clinical Advisor
Matilde Inglese - - Scientific & Clinical Advisor
Jacob B. Frieberg 65 2015 Independent Lead Director
Susan Jerian - - Scientific & Clinical Advisor
Karl Kieburtz - - Scientific Advisor
Khurram Bashir - - Scientific and Clinical Advisor
Elizabeth M. Jaffe - - Scientific & Clinical Advisor
Mark J. Tullman - - Scientific and Clinical Advisor
Anthony W. Tolcher - - Scientific and Clinical Advisor
Jeffrey A. Cohen - - Scientific & Clinical Advisor
Peter A. Calabresi - - Scientific & Clinical Advisor
Andrew D. Goodman - - Scientific & Clinical Advisor
Barbara Yanni 68 2015 Independent Director
Chrystyna Bedrij Stecyk 59 2020 Independent Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

VCNX Comments

Write your thoughts about Vaccinex Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Lyudmila Key
Lyudmila Key Mar 16, 2024 4:05PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
I think after the split you can now buy for $8, it could be crazy
Svetlana Katz
Svetlana Katz Jul 17, 2023 12:28PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
BUY THE DIP!
take profit
take profit Jul 17, 2023 10:40AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
$0.3 - that's a bargain time to buy
Nick Wilson
Nick Wilson Oct 18, 2022 7:57AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
VCNX, Better get your *******in gear…
Ab High
Ab High Jan 26, 2022 11:42AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
.93$
Nick Wilson
Nick Wilson Dec 18, 2021 7:18PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Chirp, chirp, chirp…..anyone else still here?? Lol…
Nick Wilson
Nick Wilson Aug 23, 2021 8:35PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Make a move!!!! Stop running sideways…
فيصل ابوعبدالله
فيصل ابوعبدالله Feb 22, 2021 9:15AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Does anyone knows, where it will go in near future?
Davis Sandhosh
Davis Sandhosh Feb 22, 2021 9:15AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
In future all will die
Osama Alwaely
Osama Alwaely Feb 19, 2021 2:22PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Fake stock yes
Erkin Gurbanzade
Erkin Gurbanzade Feb 19, 2021 1:52PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
hope u get bankrupt soon, fake stock
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email